Neovasculogenic therapy to augment perfusion and preserve viability in ischemic cardiomyopathy.

@article{Atluri2006NeovasculogenicTT,
  title={Neovasculogenic therapy to augment perfusion and preserve viability in ischemic cardiomyopathy.},
  author={Pavan Atluri and George Paul Liao and Corinna M. Panlilio and Vivian M. Hsu and Matthew J Leskowitz and Kevin J. Morine and Jeffrey E. Cohen and Mark F. Berry and Erik E Suarez and Danielle A Murphy and William M. F. Lee and Timothy J Gardner and H Lee Sweeney and Yiping Joseph Woo},
  journal={The Annals of thoracic surgery},
  year={2006},
  volume={81 5},
  pages={1728-36}
}
BACKGROUND Ischemic cardiomyopathy is a global health concern with limited therapy. We recently described endogenous revascularization utilizing granulocyte-macrophage colony stimulating factor (GMCSF) to induce endothelial progenitor cell (EPC) production and intramyocardial stromal cell-derived factor-1alpha (SDF) as a specific EPC chemokine. The EPC… CONTINUE READING